학술논문

Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in 'suboptimal' patients with advanced gastric cancer (AGC). TTD 08-02.
Document Type
Academic Journal
Source
Cancer Chemotherapy & Pharmacology (CANCER CHEMOTHER PHARMACOL), Feb2015; 75(2): 319-324. (6p)
Subject
Language
English
ISSN
0344-5704